You have no items in your shopping cart.

simulation page

The Sanofi-Aventis Acquisition of Genzyme: Contingent Value ...
Matos, Pedro; Aleyev, Dmitriy; Xu, Chong
Share This Product
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, Chong Case F-1715 / Published October 22, 2014 / 16 pages.
Format Price Quantity Select
This product is sold out

Product Overview

This case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme's pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (CVR). Was a CVR the magical solution to bridging the valuation gap?




Select Format
Choose your delivery format to add this product to your cart or save it to your library. Please allow 10 minutes after purchasing for delivery of your electronic materials.
  • Videos List

  • Overview

    This case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme's pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (CVR). Was a CVR the magical solution to bridging the valuation gap?

  • Learning Objectives